CN102023214B - Method for detecting influenza virus antibody through agglutination reaction based on eukaryotic cell for recombinant expression on influenza virus hemagglutinin and neuraminidase - Google Patents
Method for detecting influenza virus antibody through agglutination reaction based on eukaryotic cell for recombinant expression on influenza virus hemagglutinin and neuraminidase Download PDFInfo
- Publication number
- CN102023214B CN102023214B CN201010297200.XA CN201010297200A CN102023214B CN 102023214 B CN102023214 B CN 102023214B CN 201010297200 A CN201010297200 A CN 201010297200A CN 102023214 B CN102023214 B CN 102023214B
- Authority
- CN
- China
- Prior art keywords
- influenza virus
- eukaryotic
- neuraminidase
- recombinant expressed
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to the technical field of biology, in particular to a method for detecting an influenza virus antibody through agglutination reaction based on an eukaryotic cell for recombinant expression on influenza virus hemagglutinin and neuraminidase. The method comprises the following steps of: taking the eukaryotic cell for the recombinant expression on the influenza virus hemagglutinin and the neuraminidase as an agglutination reaction matrix, and detecting the influenza virus hemagglutinin antibody and the neuraminidase antibody in a sample to be detected through the recombinant expression of the influenza virus hemagglutinin and the neuraminidase in the agglutination reaction way. In the invention, the influenza virus hemagglutinin and the neuraminidase are co-expressed on the surface of the eukaryotic cell, thereby effectively avoiding self-coagulation to affect the agglutination reaction due to the combination of the hemagglutinin and a cell receptor; at the same time, the invention can more widely and rapidly detect the influenza virus antibody in different serotypes.
Description
Technical field
The present invention relates to biological technical field, be specifically related to a kind of detection method of Antibody of Influenza of the eukaryotic agglutinating reaction based on recombinant expressed influenza virus hemagglutinin and neuraminidase.
Background technology
The human or animal of recovery after particular serotype influenza infection, infection, subclinical infection and vaccine inoculation, in its body fluid (as serum, bronchial perfusate, blood plasma, tissue fluid etc.), there will be flu virus hemagglutinin antibody, by detecting the antibody of particular serotype influenza virus, can judge, diagnose or make a definite diagnosis this people or this animal and whether infect the influenza virus of (comprise early infection, subclinical infection or infect then recover etc.) this particular serotype or inoculated influenza virus vaccine or evaluated it to the resistibility of particular serotype influenza virus etc.
Detect at present the method that whether has the Antibody of Influenza of a certain particular serotype in sample to be checked, mainly contain blood clotting and suppress experiment (HAI) and neutralization experiment, be about to the influenza virus elder generation and sample mix to be checked of a certain particular serotype, then add in red blood cell or sensitive cells, judge whether sample to be checked can suppress this viral hemagglutination or cytopathic effect is judged, its shortcoming is to need to use to have infective virus, and security exists hidden danger.In relating to viral experiment, according to national regulations (State Council's < < pathogenic microorganism laboratory Biosafety management regulations > >, the pathogenic microorganism register > > that infect in the < < of the Ministry of Public Health human world, highly pathogenic pathogenic microorganism laboratory and the experimental activity bio-safety that infect in the < < human world are examined management method > >) and regulation and the suggestion of WHO, the operation requirements that comprises people H2N2 and part avian influenza virus carries out in BSL-III (P3) laboratory, therefore, it is very high that the carrying out of said method requires laboratory condition, not being suitable for Site Detection and scale detects.Document also has report, utilize the pseudovirion of expression of influenza virus HA to replace having infective influenza virus and carry out HAI experiment, but technology is too complicated.
The shortcoming of said method is also to detect the antibody of influenza virus HA.Influenza virus surface mainly exists 2 kinds of glycoprotein furcellas that antigenicity is stronger, be hemagglutinin NA and neuraminidase NA, after influenza infection or subclinical infection or vaccine inoculation, human or animal's body can all produce antibody for HA and NA, just so, influenza A virus in influenza virus is divided into 16 hypotypes such as H1-H16 according to the antigenicity of HA, the antigenicity of NA is divided into 9 hypotypes such as N1-N9, in influenza A virus, according to the various combination mode of HA and NA hypotype, numerous hypotypes have been formed, as H5N1 (being H5 hypotype and the combination of N1 hypotype).Therefore,, as detected Antibody of Influenza, except need detect HA serotype, also need NA serotype to detect.At present the detection of NA serotype antibody is needed by the neuraminidase enzyme method suppressing alive, to detect separately.
Except classical HAI and neutralization experiment, the report that also useful ELISA method and latex agglutination experimental technique detect.The advantage of ELISA and latex agglutination is to detect the antibody of HA and NA.Wherein, ELISA method is to utilize recombinant expressed and influenza virus HA and/or NA purifying to detect corresponding antibody, this need to obtain the expression and purification of the recombinant protein that keeps antigentic specificity, and because influenza virus has numerous hypotypes, even if the serum cross reaction intensity of hypotype of the same race differs, the HA of different serotypes and NA antigen are carried out to the expression and purification of recombinant protein, its workload is large, technological requirement is high, batch between poor stability.Latex agglutination method is for existing other method (HAI, neutralization experiment and ELISA method), and the reaction time is short, be applicable to Site Detection, but still comes with some shortcomings.Latex agglutination experimental technique is that the influenza virus HA of recombinant expressed and purifying and/or NA albumen coupling is surperficial at inertia latex particle, utilize agglutinating reaction to detect the corresponding antibody of influenza virus, this needs influenza virus HA and the NA of recombinant expressed and purifying equally, and need acquisition to keep the expression and purification of the recombinant protein of antigentic specificity, as detected influenza virus HA and the NA antibody of different serotypes, just need to carry out recombinant expressed and purifying to the HA of different strains and NA, the same with ELISA method, exist workload large, technological requirement is high, the problem such as poor stability between batch.
Owing to detecting Antibody of Influenza, whether people or this animal are infected and (comprise early infection, subclinical infection or infect after recover etc.) influenza virus of this particular serotype, or inoculated influenza virus vaccine, or evaluate that it is significant to resistibility of particular serotype influenza virus etc., and current HAI, neutralization experiment, the detection means such as ELISA and latex agglutination, maybe need to use and there is infective virus, or the specific experiment condition of needs and equipment, or complex process, or detect the shortcomings such as length consuming time, therefore, a kind of easy, fast, technique is relatively simple and easy to control, influenza virus HA can be detected simultaneously and NA antibody detection method is with a wide range of applications.
Summary of the invention
The object of the invention is to according to the complex process existing in the method for detection of Antibody of Influenza in prior art, detect the problems such as length consuming time, poor stability, a kind of detection method of Antibody of Influenza of the eukaryotic agglutinating reaction based on recombinant expressed influenza virus hemagglutinin and neuraminidase of quick, easy, good stability is provided.
This method above-mentioned purpose is achieved by the following technical programs:
The inventive method is by transfecting eukaryotic cells after influenza virus hemagglutinin gene and Neuraminidase Gene clone, make the eukaryotic recombinant expressed influenza virus hemagglutinin in surface and neuraminic acid zymoprotein, flu virus hemagglutinin antibody in sample to be checked and neuraminic acid enzyme antibody are combined, there is agglutinating reaction, according to whether there is agglutinating reaction, detect the Antibody of Influenza in sample to be checked
Particularly, the present invention is based on the Antibody of Influenza detection method of the eukaryotic agglutinating reaction of recombinant expressed influenza virus hemagglutinin (HA) and neuraminidase (NA), the cell of recombinant expressed influenza virus HA and NA of take is carrier, NA can destroy the acceptor of cell surface HA, prevent that nonspecific autoagglutination from appearring in cell, utilize the antigenicity of the recombinant expressed HA of cell surface and NA simultaneously, by agglutinating reaction, detect the antibody that whether has respective streams Influenza Virus in sample to be checked.
Influenza virus comprises influenza A virus, influenza B virus and influenza virus C, wherein the HA of influenza A virus can be divided into 16 hypotypes, NA can be divided into 9 hypotypes, simultaneously, sudden change and evolution due to influenza virus HA and NA, even the HA of same hypotype and NA, the power of its cross reactivity differs.Therefore, while detecting a certain particular serotype Antibody of Influenza, use method of the present invention, the eukaryotic of the HA of recombinant expressed this particular serotype strain and sample to be checked are carried out to aggegation experiment.Above-mentioned influenza virus HA, refer to H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, the H16 hypotype of influenza A virus, and the hemagglutinin of influenza B virus, influenza virus C, can be according to the HA that need to use a certain particular serotype of testing goal or its part.Above-mentioned influenza virus NA, refers to N1, N2, N3, N4, N5, N6, N7, N8, N9 hypotype and the influenza B virus of influenza A virus, the neuraminidase of influenza virus C.Above-mentioned recombinant expressed influenza virus HA and NA can be arbitrary array modes of above-mentioned different HA and NA.
As a kind of preferred version, described flu virus hemagglutinin antibody and neuraminic acid enzyme antibody are one or more the potpourri in IgG, IgM, IgA, IgE, IgD.
The Antibody of Influenza of carrying out in this way more extensive serotype detects, can carry out antigenicity analysis according to HA and the NA of detected object serotype strain, select antigenicity is conservative or antigenic cross property is strong HA and a part for NA albumen to carry out recombinant expressed eukaryotic structure, utilize agglutinating reaction to detect the Antibody of Influenza of more extensive serotype.Above-mentioned influenza virus HA and NA, can be a certain influenza virus strain HA and NA or wherein a part of, also can be the HA of various flows Influenza Virus strain and NA or wherein splicing or the mixing of a part or different HA and NA, also can be that infected by influenza HA and NA suddenly change and modify, also can be artificial synthetic natural non-existent sequence, but its core is recombination expression product, there is the antigenicity of influenza virus HA and NA.
Above-mentioned recombinant expressed influenza virus HA and the eukaryotic of NA, refer to and have the genetic fragment of influenza virus HA and NA to import eukaryotic coding, at HA and the NA of the recombinant expressed influenza virus in eukaryotic surface.Eukaryotic can be yeast, mammalian cell, insect cell, and other eukaryotic, and recombinant expressed influenza virus HA and NA are positioned at cell membrane or cell membrane surface.Wherein, eukaryotic preferred mammal cell and insect cell, its recombinant expressed influenza virus hemagglutinin can have and more approaches virus infections posttranslational modification that human or animal obtains, steric configuration and antigenicity, and the atopic of itself and influenza virus corresponding antibodies is better.Further, the recombinant expressed influenza virus HA of preferred mammal cell and NA.Recombinant expressed can be transient expression, can be also stably express.It can be DNA that coding has the genetic fragment of influenza virus HA and NA, also can be RNA, it can be the simple fragment that contains promoter and coded sequence, also can be plasmid, also can be viral vectors, it is encoding influenza virus HA and NA only, also can be simultaneously or other albumen of independent hybrid coding or polypeptide or peptide section, and its objective is the genetic fragment of encoding influenza virus HA and NA is obtained recombinant expressed in eukaryotic.Import eukaryotic mode and can use electric shock, liposome transfection, virus-mediated etc., object is that the genetic fragment of encoding influenza virus HA and NA is entered to eukaryotic is recombinant expressed to obtain.Above-mentioned recombinant expressed HA and the eukaryotic of NA, its core is to obtain the eukaryotic that has influenza virus HA and NA at cell surface expression, its objective is the antigenicity of utilizing expressed HA and NA, by aggegation, tests, and detects Antibody of Influenza.In one embodiment of the invention, announced the eukaryotic method of recombinant expressed influenza virus HA and NA.
As a kind of preferred version, above-mentioned recombinant expressed influenza virus HA and the eukaryotic of NA, as the particulate antigen matrix for agglutinating reaction, it can be the eukaryotic of natural recombinant expressed influenza virus hemagglutinin, or process through pancreatin, mechanical dispersion, enzymolysis disperses, fixing agent is fixed, stabilizer treatment, antiseptic process etc. technique simultaneously or the eukaryotic of the recombinant expressed influenza virus hemagglutinin of selectivity after processing, better to make " agglutinating reaction matrix ", preserve, prevent self-solidifying, increase sensitivity and stability that agglutinating reaction detects.In one embodiment of the invention, announced the eukaryotic disposal route of recombinant expressed influenza virus hemagglutinin HA and NA, the sensitivity and the stability that to improve agglutinating reaction, detect.
As a kind of preferred version, in detection method of the present invention, described eukaryotic is yeast, mammalian cell, insect cell or other eukaryotic, and recombinant expressed influenza virus hemagglutinin is positioned at cell membrane or cell membrane surface.
As a kind of preferred version, the influenza virus hemagglutinin of described eukaryotic surface expression and the ratio of neuraminidase are: 1: 19～19: 1; When ratio is 1: 3～9: 1, effect is better, best results when ratio is 4: 1.
Compared with prior art, the present invention has following beneficial effect:
The present invention is that to take the cell of recombinant expressed influenza virus HA and NA be carrier, utilizes agglutinating reaction, detects the antibody that whether has respective streams Influenza Virus in sample to be checked.Utilize HA and NA gene or its fragment of RT-PCR clone particular serotype influenza virus, build carrier for expression of eukaryon, transfecting eukaryotic cells, can there is recombinant expressed HA and NA in cell surface, after hydroformylation is fixing, this cell becomes the sensitization particle that HA and NA antigen are contained in surface, after sample mix to be checked, as the antibody that contains influenza virus in sample to be checked, can there is at several minutes agglutinating reaction.The method does not relate to and has infective virion; Compare ELISA, HAI and neutralization and test required a few hours to a couple of days, the reaction of the cell agglutination of recombinant expressed HA and NA only needs several minutes, and the reaction time is quick; Utilize universal primer and carrier to clone and transfection expression the HA of different serotypes and NA gene, can obtain the sensitized cell particle of different HA and NA antigen, can to different serotypes influenza virus, detect more widely.
Embodiment
Below in conjunction with embodiment, further explain the present invention, but embodiment does not limit in any form to the present invention.
The structure of the eukaryon expression plasmid of embodiment 1 influenza virus HA and NA
It is example that the present embodiment be take the strain A/Chicken/Guangdong/1/2005 (H5N1) of a strain H5 hypotype, carries out the preparation of recombinant expressed influenza virus hemagglutinin HA eukaryotic expression cell.A/Chicken/Guangdong/1/2005 (H5N1) is the separated strain H5N1 subtype influenza virus obtaining in the chicken in 2005 Nian Guangdong Province, the gene order of its HA and NA can obtain on public database GenBank, the sequence number of HA is EU874899.2, and the sequence number of NA is EU874900.2.To after this strain virus propagation, use Viral RNA Miniprep Kit to extract viral RNA, with Uni-12 primer (5 '-AGCAAAAGCAGG-3 ') and SuperScript III or M-MLV reverse transcriptase, carry out reverse transcription, obtain viral cDNA.According to the gene order of this strain HA, design a pair of primer for HA full-length gene clone, its primer sequence is specific as follows: upstream primer H5HA-F, sequence is 5 '-GCAAAGCTTACCATGGAGAAAATAGTACTTCTTC-3 ', from 5 ' end, is followed successively by 3 protectiveness bases, Hind III restriction enzyme site, KOZAK sequence, initiation codon and collochore; Downstream primer H5HA-R, sequence is 5 '-CTCGGATCCTTAAATGCAAATTCTGCATTGTAAG-3 ', from 5 ' end, is followed successively by 3 protectiveness bases, BamH I restriction enzyme site, terminator codon and collochore.Utilize this to primer, with high-fidelity Taq enzyme, viral cDNA is carried out to pcr amplification, amplification HA fragment.According to the gene order of this strain NA, design a pair of primer for NA full-length gene clone, its primer sequence is specific as follows: upstream primer N1NA-F: sequence is 5 '-GCAAAGCTTACCATGAATCCAAATCAGAAG-3 ', from 5 ' end, is followed successively by 3 protectiveness bases, Hind III restriction enzyme site, KOZAK sequence, initiation codon and collochore; Downstream primer N1NA-R, sequence is: 5 '-CTCGGATCCCTACTTGTCAATGGTGAATG-3 ', is followed successively by 3 protectiveness bases, BamH I restriction enzyme site, terminator codon and collochore from 5 ' end.Utilize this to primer, with high-fidelity Taq enzyme, viral cDNA is carried out to pcr amplification, amplification NA fragment.
PCR product is after agarose gel electrophoresis reclaims after HA and NA genetic fragment, use respectively Hind III and BamH I double digestion with expression vector pcDNA3, electrophoresis utilizes after reclaiming that HA fragment after T4DNA ligase cuts back to close enzyme is connected with carrier, NA fragment is connected with carrier again, transform respectively escherichia coli DH5a competent cell, coating Amp resistant panel.Bacterium colony, after PCR, extracts plasmid enzyme restriction and identifies and DNA sequencing, and obtaining the eukaryon expression plasmid that contains HA genetic fragment is pcDNA-H5HA, and obtaining the eukaryon expression plasmid that contains HA genetic fragment is pcDNA-N1NA.The bacterium that contains pcDNA-H5HA plasmid and pcDNA-N1NA plasmid, respectively after the LB overnight incubation of the ampicillin through containing 50 μ g/ml (Amp), with high-purity plasmid extraction kit, extract pcDNA-H5HA plasmid and pcDNA-N1NA plasmid, for follow-up transfectional cell and recombinant expressed experiment.
The eukaryotic preparation of recombinant expressed influenza virus HA of 2 while of embodiment and NA
According to Lipofectamine 2000 kit explanations, by 2.5 μ g pcDNA-H5HA plasmids, 0.5 μ gpcDNA-N1NA plasmid and 10 μ l Lipofectamine 2000 transfection composites, 35mm diameter double dish of transfection contains Human Embryonic Kidney HEK-239 cell that stand density is about 80%-90% fusion rate, after transfection, 6h removes transfection composite, changes fresh complete medium (the DMEM nutrient culture media that contains 10% hyclone).
After transfection, HEK-239 cell gets final product instantaneous recombinant expressed HA and NA, obtains the cell of instantaneous recombinant expressed influenza virus HA and NA.
For further optimization, can screen and obtain the cell of stablizing recombinant expressed HA and NA: after transfection 72h, transfectional cell piping and druming be disperseed, by in a new 35mm diameter double dish of 1/20 inoculation of cell suspension, supplement complete medium to 3ml, through spend the night adherent after, add G418 to concentration be 600 μ g/ml.After this replacing of every 3 to 5 days once contains the complete medium of 600 μ g/ml G418, the drug-resistant colonies that after approximately 3 weeks, visible screening occurs.Drug-resistant colonies, after trypsinization, is inoculated to 96 orifice plates by 10-20 cell/ml and is cultivated, add the complete medium that contains 600 μ g/ml G418 to be cultured to and grow to after individual layer, go down to posterity, obtain for detection of backup cultivate 96 orifice plates.The cell that detects 96 orifice plates of use is fixed to 5 minutes by 4% paraformaldehyde room temperature, after PBS rinsing, add the antibody of the fluorescently-labeled anti-H5 hypotype HA of Cy3 and the antibody of the fluorescently-labeled anti-N1 hypotype NA of FITC to carry out immunofluorescence detection, select red and green fluorescence positive signal by force, redness and the high hole of gfp positive cell ratio, cell is continued to the cloning and the immunofluorescence that repeat, approach 100% to positive cell ratio, can obtain stablizing the cell of recombinant expressed this strain HA and NA.
The eukaryotic processing of recombinant expressed influenza virus HA of 3 while of embodiment and NA
Instantaneous or stablize the cell of recombinant expressed this strain HA and NA, through adherent or suspend and cultivate after, with the PBS that contains 2%BSA, cell piping and druming is disperseed, cell suspension is carried out centrifugal, remove after supernatant with the PBS that contains 2%BSA by 10
7individual/ml cell density carries out resuspended.Remove supernatant, with isopyknic PBS is resuspended, centrifugal, wash 2 times, again add isopyknic PBS, add isopyknic 10% cold formaldehyde, in 4 ℃, fix 2 hours.Through the mode centrifugal, PBS is resuspended, carry out 3 washings.Finally by cell precipitation, by 10
7the concentration of individual/ml is resuspended in the PBS damping fluid that contains 0.2% Nepal gold ester, 2%BSA, 20% glycerine, 0.5% heparin, can stably preserve for a long time, has obtained recombinant expressed HA after processing and the eukaryotic of NA antigen.
Embodiment 4 is used the eukaryotic of common recombinant expressed influenza virus HA and NA to carry out agglutinating reaction and detects Antibody of Influenza
1 of the eukaryotic suspension of the recombinant expressed HA after the processing in embodiment 2 and NA antigen (approximately 50 μ l) is added on clean microslide, then the sample to be checked (serum, bronchial perfusate, blood plasma, tissue fluid etc.) that adds 50 μ l, rock gently microslide all around or use micropipette tip to be mixed, within room temperature 1-3 minute, observe whether occur cell agglutination.
Set up positive serum and negative serum contrast, as control sample meets expected results, when not aggegation occurs sample to be checked, illustrate in sample to be checked and do not contain with this strain HA and/or NA and there is the detectable concentration that reactive influenza virus HA and/or NA antibody or antibody concentration can reach lower than the method.
During sample generation aggegation to be checked, illustrate in sample to be checked and contain with this strain HA and/or NA and there is reactive influenza virus HA and/or NA antibody.Now can further carry out relative quantitative assay,, sample 1 to be checked is carried out to continuous doubling dilution, then respectively with embodiment 2 in processing after recombinant expressed HA and/or the eukaryotic suspension of NA antigen carry out agglutinating reaction, the high dilution of sample that obtains occurring aggegation, is made as d1.Same method can obtain the high dilution d2 of the agglutinating reaction positive of sample 2 to be checked.Concentration difference and relative scale with influenza virus HA and/or NA antibody in the different samples to be checked of this lateral comparison.
The eukaryotic preparation of the independent recombinant expressed influenza virus HA of embodiment 5 and NA
According to Lipofectamine 2000 kit explanations, by 3 μ g pcDNA-H5HA plasmids and 10 μ lLipofectamine 2000 transfection composites, 35mm diameter double dish of transfection contains Human Embryonic Kidney HEK-239 cell that stand density is about 80%-90% fusion rate, after transfection, 6h removes transfection composite, changes fresh complete medium (the DMEM nutrient culture media that contains 10% hyclone).
After transfection, HEK-239 cell gets final product instantaneous recombinant expressed HA, obtains the cell of instantaneous recombinant expressed influenza virus HA.
For further optimization, can screen and obtain the cell of stablizing recombinant expressed HA: after transfection 72h, transfectional cell piping and druming be disperseed, by in a new 35mm diameter double dish of 1/20 inoculation of cell suspension, supplement complete medium to 3ml, through spend the night adherent after, add G418 to concentration be 600 μ g/ml.After this replacing of every 3 to 5 days once contains the complete medium of 600 μ g/ml G418, the drug-resistant colonies that after approximately 3 weeks, visible screening occurs.Drug-resistant colonies, after trypsinization, is inoculated to 96 orifice plates by 10-20 cell/ml and is cultivated, add the complete medium that contains 600 μ g/ml G418 to be cultured to and grow to after individual layer, go down to posterity, obtain for detection of backup cultivate 96 orifice plates.The cell that detects 96 orifice plates of use is fixed to 5 minutes by 4% paraformaldehyde room temperature, after PBS rinsing, to be that primary antibodie, Cy3 fluorescently-labeled two is anti-carry out immunofluorescence detection to the antibody that adds anti-H5 hypotype HA, select the hole that fluorescence positive signal is strong, fluorescencepositive cell ratio is high, cell is continued to the cloning and the immunofluorescence that repeat, approach 100% to positive cell ratio, can obtain stablizing the cell of recombinant expressed this strain HA.
According to Lipofectamine 2000 kit explanations, by 3 μ g pcDNA-N1NA plasmids and 10 μ lLipofectamine 2000 transfection composites, 35mm diameter double dish of transfection contains Human Embryonic Kidney HEK-239 cell that stand density is about 80%-90% fusion rate, after transfection, 6h removes transfection composite, changes fresh complete medium (the DMEM nutrient culture media that contains 10% hyclone).
After transfection, HEK-239 cell gets final product instantaneous recombinant expressed NA, obtains the cell of instantaneous recombinant expressed influenza virus NA.
For further optimization, can screen and obtain the cell of stablizing recombinant expressed NA: after transfection 72h, transfectional cell piping and druming be disperseed, by in a new 35mm diameter double dish of 1/20 inoculation of cell suspension, supplement complete medium to 3ml, through spend the night adherent after, add G418 to concentration be 600 μ g/ml.After this replacing of every 3 to 5 days once contains the complete medium of 600 μ g/ml G418, the drug-resistant colonies that after approximately 3 weeks, visible screening occurs.Drug-resistant colonies, after trypsinization, is inoculated to 96 orifice plates by 10-20 cell/ml and is cultivated, add the complete medium that contains 600 μ g/ml G418 to be cultured to and grow to after individual layer, go down to posterity, obtain for detection of backup cultivate 96 orifice plates.The cell that detects 96 orifice plates of use is fixed to 5 minutes by 4% paraformaldehyde room temperature, after PBS rinsing, to be that primary antibodie, Cy3 fluorescently-labeled two is anti-carry out immunofluorescence detection to the antibody that adds anti-N1 hypotype NA, select the hole that fluorescence positive signal is strong, fluorescencepositive cell ratio is high, cell is continued to the cloning and the immunofluorescence that repeat, approach 100% to positive cell ratio, can obtain stablizing the cell of recombinant expressed this strain NA.
The eukaryotic processing of the independent recombinant expressed influenza virus HA of embodiment 6 and NA
Instantaneous or stablize the cell of recombinant expressed this strain HA, after cultivating, with the gentle vitellophag of low concentration pancreatin (0.05%) approximately 5 minutes, add the nutrient culture media cessation reaction that contains hyclone, cell suspension is carried out centrifugal, after removal supernatant, use the PBS that contains 2%BSA to carry out resuspended, obtain the cell suspension after pancreatin is processed.For preventing that cell that HA may cause is from aggegation, in cell suspension after pancreatin is processed, add neuraminidase (to claim again neuraminidase, Neuraminidase) process, eliminate the effect of recombinant expressed HA and cell autoreceptor, avoid cell autoagglutination.; by cell suspension after centrifugal; with 50mM sodium citrate (pH 6.0) damping fluid; cell is undertaken resuspended by 107/ml; the neuraminidase that adds 200 units in every ml cell suspension, centrifugal process 30 minutes under 37 ℃ of conditions after, remove supernatant; with isopyknic PBS is resuspended, centrifugal, wash 2 times, again add isopyknic PBS.The above-mentioned cell suspension of processing through pancreatin and neuraminidase, adds isopyknic 10% cold formaldehyde, in 4 ℃, fixes 2 hours.Through the mode centrifugal, PBS is resuspended, carry out 3 washings.Finally by cell precipitation, by 10
7the concentration of individual/ml is resuspended in the PBS damping fluid that contains 0.2% Nepal's gold ester, 2%BSA, 20% glycerine, 0.5% heparin, can stably preserve for a long time, has obtained the eukaryotic of the recombinant expressed HA antigen after processing.Instantaneous or stablize the cell of recombinant expressed this strain NA, through adherent or suspend and cultivate after, with the PBS that contains 2%BSA, cell piping and druming is disperseed, cell suspension is carried out centrifugal, remove after supernatant with the PBS that contains 2%BSA by 10
7individual/ml cell density carries out resuspended.Remove supernatant, with isopyknic PBS is resuspended, centrifugal, wash 2 times, again add isopyknic PBS, add isopyknic 10% cold formaldehyde, in 4 ℃, fix 2 hours.Through the mode centrifugal, PBS is resuspended, carry out 3 washings.Finally by cell precipitation, by 10
7the concentration of individual/ml is resuspended in the PBS damping fluid that contains 0.2% Nepal's gold ester, 2%BSA, 20% glycerine, 0.5% heparin, can stably preserve for a long time, has obtained the eukaryotic of the recombinant expressed NA antigen after processing.
The eukaryotic of above-mentioned independent recombinant expressed HA and NA is available detection, also both can be mixed by a certain percentage simultaneously, blending ratio is that the eukaryotic content of recombinant expressed HA is 10%-95%, preferred 70%-80%, the eukaryotic content of recombinant expressed HA is 5%-90%, preferred 20%-30%, mixed cell is similar with the eukaryotic of common recombinant expressed HA and NA in detection effect.
That embodiment 6 is used is common, separately and mix the agglutinating reaction that the eukaryotic of recombinant expressed influenza virus HA and NA is optimized and detect Antibody of Influenza
By the eukaryotic suspension (being made as A) of recombinant expressed HA antigen, the eukaryotic suspension (being made as B) of recombinant expressed NA antigen, the eukaryotic suspension of recombinant expressed HA and NA antigen (or the eukaryotic mixing suspension of single expression HA and NA, be made as C), respectively adding 1 (approximately 50 μ l) is added on clean microslide, then sample (the serum to be checked that respectively adds 50 μ l, bronchial perfusate, blood plasma, tissue fluid etc.) to 3 kinds of different cell suspensions, rock gently microslide all around or use micropipette tip to be mixed, within under room temperature 1-3 minute, observe whether occur cell agglutination.
Set up positive serum and negative serum contrast, as control sample meets expected results, sample to be checked occurs, to illustrate in sample to be checked and do not contain with this strain HA and NA and have the detectable concentration that reactive influenza virus HA and NA antibody or antibody concentration can reach lower than the method all not during aggegation with above-mentioned cell suspension.Set up positive serum and negative serum contrast, as control sample meets expected results, when sample to be checked occurs all aggegation to occur with above-mentioned cell suspension, illustrate in sample to be checked and contain with this strain HA and NA and there is reactive influenza virus HA and NA antibody.
Set up positive serum and negative serum contrast, as control sample meets expected results, when sample to be checked occurs all aggegation to occur with cell suspension A and cell suspension C, and while there is not aggegation with cell suspension B, illustrate in sample to be checked and contain with this strain HA and there is reactive influenza virus HA antibody not there is and do not contain with this strain NA the detectable concentration that reactive influenza virus NA antibody or antibody concentration can reach lower than the method.
Set up positive serum and negative serum contrast, as control sample meets expected results, when sample to be checked occurs all aggegation to occur with cell suspension B and cell suspension C, and while there is not aggegation with cell suspension A, illustrate in sample to be checked and contain with this strain NA and there is reactive influenza virus NA antibody not there is and do not contain with this strain HA the detectable concentration that reactive influenza virus HA antibody or antibody concentration can reach lower than the method.
During sample generation aggegation to be checked, illustrate in sample to be checked and contain with this strain HA and/or NA and there is reactive influenza virus HA and/or NA antibody.Now can further carry out relative quantitative assay,, sample 1 to be checked is carried out to continuous doubling dilution, then respectively with embodiment 2 in processing after recombinant expressed HA and/or the eukaryotic suspension of NA antigen carry out agglutinating reaction, the high dilution of sample that obtains occurring aggegation, is made as d1.Same method can obtain the high dilution d2 of the agglutinating reaction positive of sample 2 to be checked.Concentration difference and relative scale with influenza virus HA and/or NA antibody in the different samples to be checked of this lateral comparison.
The Antibody of Influenza detection method sequence table of the eukaryotic agglutinating reaction based on recombinant expressed influenza virus hemagglutinin and neuraminidase
SEQUENCE LISTING
<110> Medical College of Shantou University
The influenza virus of the eukaryotic agglutinating reaction of <120> based on recombinant expressed influenza virus hemagglutinin and neuraminidase
Antibody detection method
<130>
<160>5
<170>PatentIn version 3.2
<210>1
<211>12
<212>DNA
<213> artificial sequence
<400>1
agcaaaagca gg 12
<210>2
<211>34
<212>DNA
<213> artificial sequence
<400>2
gcaaagctta ccatggagaa aatagtactt cttc 34
<210>3
<211>34
<212>DNA
<213> artificial sequence
<400>3
ctcggatcct taaatgcaaa ttctgcattg taag 34
<210>4
<211>30
<212>DNA
<213> artificial sequence
<400>4
gcaaagctta ccatgaatcc aaatcagaag 30
<210>5
<211>29
<212>DNA
<213> artificial sequence
<400>5
ctcggatccc tacttgtcaa tggtgaatg 29
Claims (9)
1. the detection method of the non-diagnostic purpose of the Antibody of Influenza of the eukaryotic agglutinating reaction based on recombinant expressed influenza virus hemagglutinin and neuraminidase, it is characterized in that described method is by transfecting eukaryotic cells after influenza virus hemagglutinin gene and Neuraminidase Gene clone, make the eukaryotic recombinant expressed influenza virus hemagglutinin in surface and neuraminic acid zymoprotein, flu virus hemagglutinin antibody as agglutinating reaction matrix in sample to be checked and neuraminic acid enzyme antibody are combined, there is agglutinating reaction, according to whether there is agglutinating reaction, detect the Antibody of Influenza in sample to be checked, described eukaryotic HEK-239 cell, recombinant expressed influenza virus hemagglutinin and neuraminidase are positioned at cell membrane.
2. the detection method of the non-diagnostic purpose of the Antibody of Influenza of the eukaryotic agglutinating reaction based on recombinant expressed influenza virus hemagglutinin and neuraminidase according to claim 1, it is characterized in that described agglutinating reaction matrix is natural recombinant expressed influenza virus hemagglutinin and the eukaryotic of neuraminidase, or through pancreatin processing, mechanical dispersion, enzymolysis disperse, fixing agent is fixed, stabilizer treatment, antiseptic are processed method simultaneously or the recombinant expressed influenza virus hemagglutinin of selectivity after processing and the eukaryotic of neuraminidase.
3. the detection method of the non-diagnostic purpose of the Antibody of Influenza of the eukaryotic agglutinating reaction based on recombinant expressed influenza virus hemagglutinin and neuraminidase according to claim 1, the eukaryotic that it is characterized in that described recombinant expressed influenza virus hemagglutinin and neuraminidase is common recombinant expressed influenza virus hemagglutinin of while and neuraminidase, or the eukaryotic of recombinant expressed influenza virus hemagglutinin mixes with the eukaryotic of recombinant expressed neuraminidase respectively.
4. the detection method of the non-diagnostic purpose of the Antibody of Influenza of the eukaryotic agglutinating reaction based on recombinant expressed influenza virus hemagglutinin and neuraminidase according to claim 1, it is characterized in that influenza virus hemagglutinin and neuraminic acid zymoprotein that influenza virus hemagglutinin that described eukaryotic surface is recombinant expressed and neuraminic acid zymoprotein are complete total length, an or part for influenza virus hemagglutinin albumen and neuraminidase, or the epitope of influenza virus hemagglutinin and neuraminidase, or the partial amino-acid in influenza virus hemagglutinin and neuraminic acid zymoprotein total length or partial peptide section is suddenlyd change or modified, or influenza virus hemagglutinin and neuraminic acid zymoprotein and other albumen or polypeptide carry out amalgamation and expression or common independent expression.
5. the detection method of the non-diagnostic purpose of the Antibody of Influenza of the eukaryotic agglutinating reaction based on recombinant expressed influenza virus hemagglutinin and neuraminidase according to claim 1, it is characterized in that described recombinant expressed be transient expression or stably express.
6. the detection method of the non-diagnostic purpose of the Antibody of Influenza of the eukaryotic agglutinating reaction based on recombinant expressed influenza virus hemagglutinin and neuraminidase according to claim 1, is characterized in that the hemagglutinin of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16 hypotype, influenza B virus or influenza virus C that the recombinant expressed hemagglutinin in described eukaryotic surface is influenza A virus.
7. the detection method of the non-diagnostic purpose of the Antibody of Influenza of the eukaryotic agglutinating reaction based on recombinant expressed influenza virus hemagglutinin and neuraminidase according to claim 1, is characterized in that the neuraminidase of N1, N2, N3, N4, N5, N6, N7, N8, N9 hypotype, influenza B virus or influenza virus C that the recombinant expressed neuraminic acid zymoprotein in described eukaryotic surface is influenza A virus.
8. the detection method of the non-diagnostic purpose of the Antibody of Influenza of the eukaryotic agglutinating reaction based on recombinant expressed influenza virus hemagglutinin and neuraminidase according to claim 1, is characterized in that described flu virus hemagglutinin antibody and neuraminic acid enzyme antibody are one or more the potpourri in IgG, IgM, IgA, IgE, IgD.
9. according to the detection method of the non-diagnostic purpose of the Antibody of Influenza of the eukaryotic agglutinating reaction based on recombinant expressed influenza virus hemagglutinin and neuraminidase described in any claim in claim 1～8, it is characterized in that the influenza virus hemagglutinin of described eukaryotic surface expression and the ratio of neuraminidase are 1:19～19:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010297200.XA CN102023214B (en) | 2010-09-28 | 2010-09-28 | Method for detecting influenza virus antibody through agglutination reaction based on eukaryotic cell for recombinant expression on influenza virus hemagglutinin and neuraminidase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010297200.XA CN102023214B (en) | 2010-09-28 | 2010-09-28 | Method for detecting influenza virus antibody through agglutination reaction based on eukaryotic cell for recombinant expression on influenza virus hemagglutinin and neuraminidase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102023214A CN102023214A (en) | 2011-04-20 |
| CN102023214B true CN102023214B (en) | 2014-04-02 |
Family
ID=43864765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010297200.XA Active CN102023214B (en) | 2010-09-28 | 2010-09-28 | Method for detecting influenza virus antibody through agglutination reaction based on eukaryotic cell for recombinant expression on influenza virus hemagglutinin and neuraminidase |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102023214B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105486871B (en) * | 2015-11-25 | 2017-07-28 | 北京世纪元亨动物防疫技术有限公司 | A kind of quick detection canine parvovirus antibody blood clotting suppresses colloidal gold strip, kit and the detection method of potency |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2006375A4 (en) * | 2006-03-23 | 2013-05-08 | Japan Red Cross | Panel cell used for granulocyte antibody detection |
| CN101833002A (en) * | 2010-04-21 | 2010-09-15 | 东北农业大学 | Antibody indirect immunofluorescence test method for distinguishing immune animal infected with influenza A virus |
-
2010
- 2010-09-28 CN CN201010297200.XA patent/CN102023214B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102023214A (en) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9849172B2 (en) | Influenza virus vaccines and uses thereof | |
| Hai et al. | Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes | |
| Reed et al. | Amino acid residues in the fusion peptide pocket regulate the pH of activation of the H5N1 influenza virus hemagglutinin protein | |
| CN112321688B (en) | Stable coronavirus recombinant protein dimer and expression vector thereof | |
| US9708373B2 (en) | Influenza virus vaccine and uses thereof | |
| CN102023212B (en) | Rapid detection method of influenza virus neuraminidase antibody | |
| CN111234036B (en) | African swine fever virus p72 fusion protein and preparation method and application thereof | |
| Herfst et al. | Hemagglutinin traits determine transmission of avian A/H10N7 influenza virus between mammals | |
| CN103547676A (en) | Immunogenic compositions in particulate form and methods for producing the same | |
| Guo et al. | Analysis of hemagglutinin-mediated entry tropism of H5N1 avian influenza | |
| CN110951699A (en) | Recombinant rabies virus for expressing structural protein of canine distemper virus and application thereof | |
| JP2023543472A (en) | Viral vectors and their use | |
| CN108348596A (en) | With the recombinant virus sample particle of bovine immunodeficiency virus Gag albumen | |
| Karakus et al. | H19 influenza A virus exhibits species-specific MHC class II receptor usage | |
| CN102023214B (en) | Method for detecting influenza virus antibody through agglutination reaction based on eukaryotic cell for recombinant expression on influenza virus hemagglutinin and neuraminidase | |
| Yan et al. | Recombinant soluble Henipavirus glycoprotein preparation | |
| CN102023215B (en) | Influenza virus antibody detection method based on eukaryotic cell agglutination reaction of recombined expression influenza virus hemagglutinin | |
| CN102023213B (en) | Fluorescence micro cell agglutination method for detecting influenza virus antibody | |
| CN112430273A (en) | Subunit fusion protein mG on rabies virus surface as well as preparation method and application thereof | |
| Boumaiza et al. | Development of an optimized process for functional recombinant SARS-CoV-2 spike S1 receptor-binding domain protein produced in the baculovirus expression vector system | |
| CN106520699A (en) | Recombinant HEK-293T cell and Zika virus resistant fusion protein secreted by recombinant HEK-293T cell | |
| Noisumdaeng et al. | Homosubtypic and heterosubtypic antibodies against highly pathogenic avian influenza H5N1 recombinant proteins in H5N1 survivors and non-H5N1 subjects | |
| CN102190701B (en) | Method for separating and purifying influenza virus hemagglutinin on large scale | |
| Zhu et al. | System for the heterologous expression of NS1 protein of H9N2 avian influenza virus in the ciliate Tetrahymena thermophila | |
| Feng et al. | H9 subtype influenza vaccine in MDCK single‐cell suspension culture with stable expression of TMPRSS2: Generation and efficacy evaluation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |